173 related articles for article (PubMed ID: 27099522)
41. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Gallego Rubio O; Bonfill Cosp X; Agra Varela Y
Cochrane Database Syst Rev; 2009 Oct; (4):CD001990. PubMed ID: 19821287
[TBL] [Abstract][Full Text] [Related]
42. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.
Han JY; Lim KY; Yu SY; Yun T; Kim HT; Lee JS
Cancer; 2011 May; 117(10):2178-85. PubMed ID: 21523731
[TBL] [Abstract][Full Text] [Related]
43. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
Spigel DR; Hainsworth JD; Gandhi JG; Gian VG; Peyton JD; West-Osterfield K; Clark BL; Vazquez ER; Jones SF; Burris HA; Greco FA
J Thorac Oncol; 2010 Jun; 5(6):862-6. PubMed ID: 20521352
[TBL] [Abstract][Full Text] [Related]
44. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
45. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
[TBL] [Abstract][Full Text] [Related]
46. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
[TBL] [Abstract][Full Text] [Related]
47. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
48. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Steffens CC; Elender C; Hutzschenreuter U; Dille S; Binninger A; Spring L; Jänicke M; Marschner N;
Lung Cancer; 2019 Apr; 130():216-225. PubMed ID: 30885347
[TBL] [Abstract][Full Text] [Related]
49. Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer.
Kim C; Sohn JH; Kim JH; Kim SK; Kim YS; Chang J; Cho JY
Cancer Res Treat; 2002 Oct; 34(5):334-8. PubMed ID: 26680884
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
51. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
52. Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study.
Wang K; Long W; Sima X; Zhao Y; Xiao B; Gulizeba H; Huang Y
J Thorac Dis; 2022 Jul; 14(7):2645-2651. PubMed ID: 35928624
[TBL] [Abstract][Full Text] [Related]
53. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Choi HJ; Cho BC; Shin SJ; Cheon SH; Jung JY; Chang J; Kim SK; Sohn JH; Kim JH
Cancer Chemother Pharmacol; 2008 Feb; 61(2):309-13. PubMed ID: 17576560
[TBL] [Abstract][Full Text] [Related]
54. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Ardizzoni A; Hansen H; Dombernowsky P; Gamucci T; Kaplan S; Postmus P; Giaccone G; Schaefer B; Wanders J; Verweij J
J Clin Oncol; 1997 May; 15(5):2090-6. PubMed ID: 9164222
[TBL] [Abstract][Full Text] [Related]
55. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
56. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
[TBL] [Abstract][Full Text] [Related]
57. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
58. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
59. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
[TBL] [Abstract][Full Text] [Related]
60. Irinotecan as a second-line monotherapy for small cell lung cancer.
Sevinc A; Kalender ME; Altinbas M; Ozkan M; Dikilitas M; Camci C;
Asian Pac J Cancer Prev; 2011; 12(4):1055-9. PubMed ID: 21790251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
